These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 23787720)

  • 1. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
    Girerd N; Pang PS; Swedberg K; Fought A; Kwasny MJ; Subacius H; Konstam MA; Maggioni A; Gheorghiade M; Zannad F;
    Eur J Heart Fail; 2013 Nov; 15(11):1228-35. PubMed ID: 23787720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
    Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
    Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP
    Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
    Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M;
    Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial.
    Ambrosy AP; Vaduganathan M; Huffman MD; Khan S; Kwasny MJ; Fought AJ; Maggioni AP; Swedberg K; Konstam MA; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2012 Mar; 14(3):302-11. PubMed ID: 22357577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Ambrosy AP; Pang PS; Khan S; Konstam MA; Fonarow GC; Traver B; Maggioni AP; Cook T; Swedberg K; Burnett JC; Grinfeld L; Udelson JE; Zannad F; Gheorghiade M;
    Eur Heart J; 2013 Mar; 34(11):835-43. PubMed ID: 23293303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
    Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
    Blair JE; Khan S; Konstam MA; Swedberg K; Zannad F; Burnett JC; Grinfeld L; Maggioni AP; Udelson JE; Zimmer CA; Ouyang J; Chen CF; Gheorghiade M;
    Eur Heart J; 2009 Jul; 30(13):1666-73. PubMed ID: 19411662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Fonarow GC; Zannad F; Maggioni AP; Konstam MA; Subacius HP; Nodari S; Butler J; Gheorghiade M;
    Am J Cardiol; 2013 Dec; 112(11):1763-9. PubMed ID: 24095030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival after hospitalization for acute heart failure--differences in prognosis of acutely decompensated chronic and new-onset acute heart failure.
    Lassus JP; Siirilä-Waris K; Nieminen MS; Tolonen J; Tarvasmäki T; Peuhkurinen K; Melin J; Pulkki K; Harjola VP;
    Int J Cardiol; 2013 Sep; 168(1):458-62. PubMed ID: 23073273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
    JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
    Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
    Mentz RJ; Schmidt PH; Kwasny MJ; Ambrosy AP; O'Connor CM; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Gheorghiade M
    J Card Fail; 2012 Jul; 18(7):515-23. PubMed ID: 22748484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry.
    Oh J; Kang SM; Hong N; Youn JC; Han S; Jeon ES; Cho MC; Kim JJ; Yoo BS; Chae SC; Oh BH; Choi DJ; Lee MM; Ryu KH
    Int J Cardiol; 2013 Oct; 168(5):4739-43. PubMed ID: 23958420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure.
    Habal MV; Liu PP; Austin PC; Ross HJ; Newton GE; Wang X; Tu JV; Lee DS
    Circ Heart Fail; 2014 Jan; 7(1):12-20. PubMed ID: 24297690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.